Factor V Leiden G1691A, prothrombin G20210A, and MTHFR C677T mutations in Turkish inflammatory bowel disease patients

Basit Öğe Kaydı
dc.contributor.authorYasa, Mehmet Hadi
dc.contributor.authorBolaman, Zahit
dc.contributor.authorYukselen, Vahit
dc.contributor.authorKadikoylu, Gurhan
dc.contributor.authorKaraoglu, Ali Onder
dc.contributor.authorBatun, Sabri
dc.date.accessioned2024-04-24T17:33:57Z
dc.date.available2024-04-24T17:33:57Z
dc.date.issued2007
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground/Aims: Patients with inflammatory bowel disease (IBD) have an increased risk for thromboembolic complications. We investigated the incidence of factor V Leiden G1691A, methylene tetrahydrofolate reductase (MTHFR) C677T, and prothrombin G20210A mutation in 27 Turkish IBD patients with no history of thromboembolic disease. Methodology: Twenty-seven patients, 22 with ulcerative colitis (UC) and 5 with Crohn's disease (CD), and 47 healthy were included to the study. The DNAs were obtained from peripheral blood by using pure polymerase chain kit. Then, factor V Leiden G1691A, which active protein C resistance positive, prothrombin G20210A and MTHFR C677T mutations were investigated in DNA by using LightCycler-Factor V Leiden G1691A mutation, Prothrombin G20210A and MTHFR C677T estimate kits. Results: The heterozygote factor V Leiden G1691A mutation was detected in 3 (11.1%) patients with IBD and 2 (4.3%) controls (p > 0.05). The homozygote factor V Leiden G1691A mutation was not estimated among patients and controls. Heterozygote prothrombin G20210A mutation was detected in 2 (7.4%) patients with IBD and in 0 (0%) controls (p>0.05). There was no homozygote prothrombin G20210A mutation in IBD and controls. Heterozygote MTHFR C677T mutation was 10 of 27 (37%) patients with IBD while 15 of 47 (32%) controls (p>0.05). Homozygote MTHFR C677T mutation was detected in 4 patients (14.9%) with IBD and 3 (6.3%) controls (p>0.05). Conclusions: Our study did not reveal any association between IBD and the most common hereditary thrombophilic factors and these mutations interfere with neither disease manifestations nor the thrombotic complications.en_US
dc.identifier.endpage1442en_US
dc.identifier.issn0172-6390
dc.identifier.issue77en_US
dc.identifier.pmid17708272
dc.identifier.scopus2-s2.0-34547633637
dc.identifier.scopusqualityN/A
dc.identifier.startpage1438en_US
dc.identifier.urihttps://hdl.handle.net/11468/20903
dc.identifier.volume54en_US
dc.identifier.wosWOS:000248389500032
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherH G E Update Medical Publishing S Aen_US
dc.relation.ispartofHepato-Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFactor V Leiden G1691aen_US
dc.subjectMethylene Tetrahydrofolate Reductase C677ten_US
dc.subjectGene Mutationen_US
dc.subjectProthrombin G20210aen_US
dc.subjectInflammatory Bowel Diseaseen_US
dc.titleFactor V Leiden G1691A, prothrombin G20210A, and MTHFR C677T mutations in Turkish inflammatory bowel disease patientsen_US
dc.titleFactor V Leiden G1691A, prothrombin G20210A, and MTHFR C677T mutations in Turkish inflammatory bowel disease patients
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu